Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the target of a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 30,500 shares, a decrease of 49.0% from the December 15th total of 59,800 shares. Based on an average daily trading volume, of 111,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a report on Friday, November 8th.

Talphera Trading Up 5.6 %

TLPH traded up $0.03 during trading on Thursday, reaching $0.61. 59,370 shares of the company were exchanged, compared to its average volume of 96,419. The stock has a market cap of $10.44 million, a P/E ratio of -0.89 and a beta of 0.28. Talphera has a 52 week low of $0.50 and a 52 week high of $1.61. The firm has a 50 day moving average of $0.67 and a 200 day moving average of $0.83.

Hedge Funds Weigh In On Talphera

An institutional investor recently bought a new position in Talphera stock. Nantahala Capital Management LLC bought a new position in Talphera, Inc. (NASDAQ:TLPH) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned about 11.73% of Talphera at the end of the most recent quarter. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.